Strontium-doped hydroxyapatite nanocomposites for breast cancer bone metastasis therapy by modulating bone formation and suppressing cancer cell stemness
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Bone Tissue Engineering Materials · Bone health and treatments · Graphene and Nanomaterials Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (47)
Show source-provided references
1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229–263. https://doi.org/10.3322/caac.2183410.3322/caac.21834 ↗
2. Ording AG, Heide-Jorgensen U, Christiansen CF, Norgaard M, Acquavella J, Sorensen HT (2017) Site of metastasis and breast cancer mortality: a Danish nationwide registry-based cohort study. Clin Exp Metastas 34:93–101. https://doi.org/10.1007/s10585-016-9824-810.1007/s10585-016-9824-8 ↗
3. Wang R, Zhu Y, Liu X, Liao X, He J, Niu L (2019) The clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. BMC Cancer 19:1091. https://doi.org/10.1186/s12885-019-6311-z10.1186/s12885-019-6311-z ↗
4. Shinoda Y, Sawada R, Yoshikawa F, Oki T, Hirai T, Kobayashi H, Matsudaira K, Oka H, Tanaka S, Kawano H, Haga N (2019) Factors related to the quality of life in patients with bone metastases. Clin Exp Metastasis 36:441–448. https://doi.org/10.1007/s10585-019-09983-010.1007/s10585-019-09983-0 ↗
5. Weilbaecher KN, Guise TA, McCauley LK (2011) Cancer to bone: a fatal attraction. Nat Rev Cancer 11:411–425. https://doi.org/10.1038/nrc305510.1038/nrc3055 ↗
6. Wu MY, Li CJ, Yiang GT, Cheng YL, Tsai AP, Hou YT, Ho YC, Hou MF, Chu PY (2018) Molecular regulation of bone metastasis pathogenesis. Cell Physiol Biochem 46:1423–1438. https://doi.org/10.1159/00048918410.1159/000489184 ↗
7. Brook N, Brook E, Dharmarajan A, Dass CR, Chan A (2018) Breast cancer bone metastases: pathogenesis and therapeutic targets. Int J Biochem Cell Biol 96:63–78. https://doi.org/10.1016/j.biocel.2018.01.00310.1016/j.biocel.2018.01.003 ↗
8. Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, Gao G, Wu L, Sohn W, Jun S (2009) Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 27:1564–1571. https://doi.org/10.1200/JCO.2008.19.214610.1200/JCO.2008.19.2146 ↗
9. Zhang W, Bado IL, Hu J, Wan YW, Wu L, Wang H, Gao Y, Jeong HH, Xu Z, Hao X, Lege BM, Al-Ouran R, Li L, Li J, Yu L, Singh S, Lo HC, Niu M, Liu J, Jiang W, Zhang XH (2021) The bone microenvironment invigorates metastatic seeds for further dissemination. Cell 184:2471–2486. https://doi.org/10.1016/j.cell.2021.03.01110.1016/j.cell.2021.03.011 ↗
10. Waldum H, Slupphaug G (2024) Correctly identifying the cells of origin is essential for tailoring treatment and understanding the emergence of cancer stem cells and late metastases. Front Oncol 14:1369907. https://doi.org/10.3389/fonc.2024.136990710.3389/fonc.2024.1369907 ↗
11. Kreps LM, Addison CL (2021) Targeting intercellular communication in the bone microenvironment to prevent disseminated tumor cell escape from dormancy and bone metastatic tumor growth. Int J Mol Sci 22:2911. https://doi.org/10.3390/ijms2206291110.3390/ijms22062911 ↗
12. Wong MH, Stockler MR, Pavlakis N (2012) Bisphosphonates and other bone agents for breast cancer. Cochrane Db Syst Rev 15:CD003474. https://doi.org/10.1002/14651858.CD003474.pub310.1002/14651858.CD003474.pub3 ↗
13. Jahn-Rickert K, Wolfel EM, Jobke B, Riedel C, Hellmich M, Werner M, McDonald MM, Busse B (2020) Elevated bone hardness under denosumab treatment, with persisting lower osteocyte viability during discontinuation. Front Endocrinol 11:250. https://doi.org/10.3389/fendo.2020.0025010.3389/fendo.2020.00250 ↗
14. Jeong J, Kim JH, Shim JH, Hwang NS, Heo CY (2019) Bioactive calcium phosphate materials and applications in bone regeneration. Biomater Res 23:4. https://doi.org/10.1186/s40824-018-0149-310.1186/s40824-018-0149-3 ↗
15. Du M, Chen J, Liu K, Xing H, Song C (2021) Recent advances in biomedical engineering of nano-hydroxyapatite including dentistry, cancer treatment and bone repair. Compos Part B-Eng 215:108790. https://doi.org/10.1016/j.compositesb.2021.10879010.1016/j.compositesb.2021.108790 ↗
16. Mondal S, Park S, Choi J, Vu TTH, Doan VHM, Vo TT, Lee B, Oh J (2023) Hydroxyapatite: a journey from biomaterials to advanced functional materials. Adv Colloid Interface Sci 321:103013. https://doi.org/10.1016/j.cis.2023.10301310.1016/j.cis.2023.103013 ↗
17. Mondal S, Dorozhkin SV, Pal U (2018) Recent progress on fabrication and drug delivery applications of nanostructured hydroxyapatite. Wires Nanomed Nanobiotechnol 10:e1504. https://doi.org/10.1002/wnan.150410.1002/wnan.1504 ↗
18. Liu X, Huang H, Zhang J, Sun T, Zhang W, Li Z (2023) Recent advance of strontium functionalized in biomaterials for bone regeneration. Bioengineering 10:414. https://doi.org/10.3390/bioengineering1004041410.3390/bioengineering10040414 ↗
19. Sutthavas P, Tahmasebi Birgani Z, Habibovic P, van Rijt S (2022) Calcium phosphate-coated and strontium-incorporated mesoporous silica nanoparticles can effectively induce osteogenic stem cell differentiation. Adv Healthc Mater 11:e2101588. https://doi.org/10.1002/adhm.20210158810.1002/adhm.202101588 ↗
20. Shen X, Fang K, Ru Yie KH, Zhou Z, Shen Y, Wu S, Zhu Y, Deng Z, Ma P, Ma J, Li J (2021) High proportion strontium-doped micro-arc oxidation coatings enhance early osseointegration of titanium in osteoporosis by anti-oxidative stress pathway. Bioact Mater 10:405–419. https://doi.org/10.1016/j.bioactmat.2021.08.03110.1016/j.bioactmat.2021.08.031 ↗
21. Budakoti M, Panwar AS, Molpa D, Singh RK, Büsselberg D, Mishra AP, Coutinho HDM, Nigam M (2021) Micro-RNA: the darkhorse of cancer. Cell Signal 83:109995. https://doi.org/10.1016/j.cellsig.2021.10999510.1016/j.cellsig.2021.109995 ↗
22. Salzman DW, Nakamura K, Nallur S, Dookwah MT, Metheetrairut C, Slack FJ, Weidhaas JB (2016) MiR-34 activity is modulated through 5’-end phosphorylation in response to DNA damage. Nat Commun 7:10954. https://doi.org/10.1038/ncomms1095410.1038/ncomms10954 ↗
23. Park EY, Chang E, Lee EJ, Lee HW, Kang HG, Chun KH, Woo YM, Kong HK, Ko JY, Suzuki H, Song E, Park JH (2014) Targeting of miR34a-NOTCH1 axis reduced breast cancer stemness and chemoresistance. Cancer Res 74(24):7573–758210.1158/0008-5472.CAN-14-1140 ↗
24. Liu H, Dong Y, Feng X, Li L, Jiao Y, Bai S, Feng Z, Yu H, Li X, Zhao Y (2019) Mir-34a promotes bone regeneration in irradiated bone defects by enhancing osteoblastic differentiation of mesenchymal stromal cells in rats. Stem Cell Res Ther 10:180. https://doi.org/10.1186/s13287-019-1285-y10.1186/s13287-019-1285-y ↗
25. Jin Y, Liu X, Liu H, Chen S, Gao C, Ge K, Zhang J (2017) Oxidative stress-induced apoptosis of osteoblastic MC3T3-E1 cells by hydroxyapatite nanoparticles through lysosomal and mitochondrial pathways. RSC Adv 7:13010. https://doi.org/10.1039/C7RA01008G10.1039/C7RA01008G ↗
26. Hou H, Gao F, Liang H, Lv Y, Li M, Yao L, Zhang J, Dou G, Wang Y (2018) Microrna-188-5p regulates contribution of bone marrow-derived cells to choroidal neovascularization development by targeting MMP-2/13. Exp Eye Res 175:115–123. https://doi.org/10.1016/j.exer.2018.06.01010.1016/j.exer.2018.06.010 ↗
27. Perkins RS, Murray G, Suthon S, Davis L, Perkins NB 3rd, Fletcher L, Bozzi A, Schreiber SL, Lin J, Laxton S, Pillai RR, Wright AJ, Miranda-Carboni GA, Krum SA (2024) WNT5B drives osteosarcoma stemness, chemoresistance and metastasis. Clin Transl Med 14:e1670. https://doi.org/10.1002/ctm2.167010.1002/ctm2.1670 ↗
28. Kim JH, Park JM, Jung E, Lee J, Han J, Kim YJ, Kim JY, Seo JH, Kim JS (2022) A synchronized dual drug delivery molecule targeting cancer stem cells in tumor heterogeneity and metastasis. Biomaterials 289:121781. https://doi.org/10.1016/j.biomaterials.2022.12178110.1016/j.biomaterials.2022.121781 ↗
29. Jo G, Park Y, Park MH, Hyun H (2023) Near-infrared fluorescent hydroxyapatite nanoparticles for targeted photothermal cancer therapy. Pharmaceutics 15:1374. https://doi.org/10.3390/pharmaceutics1505137410.3390/pharmaceutics15051374 ↗
30. Angelozzi M, Charleroy CR, Lefebvre V (2021) Edu-based assay of cell proliferation and stem cell quiescence in skeletal tissue sections. Methods Mol Biol 2230:357–365. https://doi.org/10.1007/978-1-0716-1028-2_2110.1007/978-1-0716-1028-2_21 ↗
31. Fan D, Li J, Li L, An M, Yang H, Zhou G, Gao S, Bottini M, Zhang J, Ge K (2024) Phosphate ion-responsive and calcium peroxide-based nanomedicine for bone-targeted treatment of breast cancer bone metastasis. Adv Healthc Mater 13:e2402216. https://doi.org/10.1002/adhm.20240221610.1002/adhm.202402216 ↗
32. Wang S, Ni Y, Wang J, Bu Y, Yang Y, Sun X, Zhu X, Kong L, Wang S, Zhou H (2023) Construction of ROS-generation system based on lipid droplet-targeting photosensitizer to mediate multiple subcellular organelle damage. Sensor Actuat B-Chem 393:134201. https://doi.org/10.1016/j.snb.2023.13420110.1016/j.snb.2023.134201 ↗
33. Li JJ, Chen WL, Wang JY, Hu QW, Sun ZP, Zhang S, Liu S, Han XH (2017) Wenshen zhuanggu formula effectively suppresses breast cancer bone metastases in a mouse xenograft model. Acta Pharmacol Sin 38:1369–1380. https://doi.org/10.1038/aps.2017.1310.1038/aps.2017.13 ↗
34. Sugyo A, Tsuji AB, Sudo H, Sugiura Y, Koizumi M, Higashi T (2023) Wnt1 induces osteoblastic changes in a well-established osteolytic skeletal metastatic model derived from breast cancer. Cancer Rep 6:e1909. https://doi.org/10.1002/cnr2.190910.1002/cnr2.1909 ↗
35. Chen Y, Luan J, Jiang T, Cai D, Sun C, Wang X, Zhao X, Gou X (2021) Knockdown of EMMPRIN (OX47) in MRMT-1 carcinoma cells inhibits tumor growth and decreases cancer-induced bone destruction and pain. Cancer Res Treat 53:576–583. https://doi.org/10.4143/crt.2020.80110.4143/crt.2020.801 ↗
36. Deng X, Cao M, Zhang J, Hu K, Yin Z, Zhou Z, Xiao X, Yang Y, Sheng W, Wu Y, Zeng Y (2014) Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. Biomaterials 35:4333–4344. https://doi.org/10.1016/j.biomaterials.2014.02.00610.1016/j.biomaterials.2014.02.006 ↗
37. Gaur S, Wen Y, Song JH, Parikh NU, Mangala LS, Blessing AM, Ivan C, Wu SY, Varkaris A, Shi Y, Lopez-Berestein G, Frigo DE, Sood AK, Gallick GE (2015) Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. Oncotarget 6:29161–29177. https://doi.org/10.18632/oncotarget.497110.18632/oncotarget.4971 ↗
38. Bose S, Tarafder S (2012) Calcium phosphate ceramic systems in growth factor and drug delivery for bone tissue engineering: a review. Acta Biomater 8:1401–1421. https://doi.org/10.1016/j.actbio.2011.11.01710.1016/j.actbio.2011.11.017 ↗
39. Dheyab MA, Aziz AA, Khaniabadi PM, Jameel MS, Oladzadabbasabadi N, Rahman AA, Braim FS, Mehrdel B (2023) Gold nanoparticles-based photothermal therapy for breast cancer. Photodiagn Photodyn 42:103312. https://doi.org/10.1016/j.pdpdt.2023.10331210.1016/j.pdpdt.2023.103312 ↗
40. Cui C, Huo Q, Xiong X, Na S, Mitsuda M, Minami K, Li B, Yokota H (2024) P18: novel anticancer peptide from induced tumor-suppressing cells targeting breast cancer and bone metastasis. Cancers (Basel) 16:2230. https://doi.org/10.3390/cancers1612223010.3390/cancers16122230 ↗
41. Qiao X, Zhang Y, Sun L, Ma Q, Yang J, Ai L, Xue J, Chen G, Zhang H, Ji C, Gu X, Lei H, Yang Y, Liu C (2021) Association of human breast cancer CD44-/CD24-cells with delayed distant metastasis. Elife 10:e65418. https://doi.org/10.7554/eLife.6541810.7554/eLife.65418 ↗
42. Abdoli Shadbad M, Hosseinkhani N, Asadzadeh Z, Derakhshani A, Karim Ahangar N, Hemmat N, Lotfinejad P, Brunetti O, Silvestris N, Baradaran B (2021) A systematic review to clarify the prognostic values of CD44 and CD44+CD24- phenotype in triple-negative breast cancer patients: lessons learned and the road ahead. Front Oncol 11:689839. https://doi.org/10.3389/fonc.2021.68983910.3389/fonc.2021.689839 ↗
43. Escudero Mendez L, Srinivasan M, Hamouda RK, Ambedkar B, Arzoun H, Sahib I, Fondeur J, Mohammed L (2022) Evaluation of CD44+/CD24- and aldehyde dehydrogenase enzyme markers in cancer stem cells as prognostic indicators for triple-negative breast cancer. Cureus J Med Sci 14:e28056. https://doi.org/10.7759/cureus.2805610.7759/cureus.28056 ↗
44. Gu J, Chen D, Li Z, Yang Y, Ma Z, Huang G (2022) Prognosis assessment of CD44+/CD24- in breast cancer patients: a systematic review and meta-analysis. Arch Gynecol Obstet 306:1147–1160. https://doi.org/10.1007/s00404-022-06402-w10.1007/s00404-022-06402-w ↗
45. Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, Goulet R Jr, Badve S, Nakshatri H (2006) CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 8(5):R59. https://doi.org/10.1186/bcr161010.1186/bcr1610 ↗
46. Frantzias J, Logan JG, Mollat P, Sparatore A, Del Soldato P, Ralston SH, Idris AI (2012) Hydrogen sulphide-releasing diclofenac derivatives inhibit breast cancer-induced osteoclastogenesis in vitro and prevent osteolysis ex vivo. Brit J Pharmacol 165:1914–1925. https://doi.org/10.1111/j.1476-5381.2011.01704.x10.1111/j.1476-5381.2011.01704.x ↗
47. Yuan X, Qian N, Ling S, Li Y, Sun W, Li J, Du R, Zhong G, Liu C, Yu G, Cao D, Liu Z, Wang Y, Qi Z, Yao Y, Wang F, Liu J, Hao S, Jin X, Zhao Y, Li Y (2021) Breast cancer exosomes contribute to pre-metastatic niche formation and promote bone metastasis of tumor cells. Theranostics 11:1429–1445. https://doi.org/10.7150/thno.4535110.7150/thno.45351 ↗